Reverse Payment Agreement Template for the United States

When you're involved in pharmaceutical patent litigation between a brand drug company and generic manufacturer, you may need a reverse payment agreement to settle the dispute. These complex legal instruments have become essential tools in the pharmaceutical industry for resolving patent challenges while maintaining regulatory compliance under strict federal antitrust scrutiny.

When do you need this document?

You'll need a reverse payment agreement when facing Paragraph IV patent challenges under the Hatch-Waxman Act, where a generic manufacturer has filed an Abbreviated New Drug Application (ANDA) certifying that your patents are invalid or will not be infringed. These agreements become necessary when litigation costs and uncertain outcomes make settlement more attractive than continued court battles. You may also require this document when seeking to manage generic entry timing while avoiding the risk of antitrust violations that could result in treble damages and criminal penalties. Additionally, these agreements are essential when you need to satisfy FDA approval timelines while maintaining market exclusivity periods.

Key legal considerations

Your reverse payment agreement must carefully balance settlement benefits against antitrust risks identified in FTC v. Actavis. The Supreme Court established that these agreements face "rule of reason" analysis, meaning you must demonstrate that any payments serve legitimate business purposes beyond delaying generic competition. You need to ensure that payment amounts don't exceed avoided litigation costs and that any restrictions on generic entry are reasonably related to the scope and strength of your patents. The agreement must include robust justifications for payment structures, whether they involve cash, licensing deals, or other value transfers. You should also address potential FTC challenges by documenting the pro-competitive benefits, such as enabling earlier generic entry than successful patent litigation would allow.

Legal requirements in United States

Under federal law, your reverse payment agreement must comply with FTC reporting requirements mandated by the Medicare Prescription Drug, Improvement, and Modernization Act. You must file detailed reports with the FTC and DOJ within 30 days of execution, disclosing all terms including payment amounts, restricted activities, and market entry dates. The agreement must satisfy Sherman Antitrust Act provisions by avoiding unreasonable restraints on trade and ensuring that any market division reflects legitimate patent scope. You need to structure payment terms to withstand Clayton Act scrutiny, particularly regarding potential monopolization effects. Additionally, your agreement must align with FDA regulations governing ANDA approvals and comply with any court-ordered timelines from underlying patent litigation. Consider including provisions for regulatory approval contingencies and ensure that your settlement terms don't conflict with existing consent decrees or FTC enforcement actions.